MoonLake Immunotherapeutics filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a net loss of $79.5 million for the third quarter and $211.1 million for the nine months ended September 30, 2026.

Key Highlights

  • Third-quarter net loss: $79,545 thousand, compared to $70,694 thousand in the same quarter of 2025, according to the filing.
  • Nine-month net loss: $211,057 thousand for the nine months ended September 30, 2026, versus $167,303 thousand for the same period in 2025.
  • Research and development expenses: $68,871 thousand for Q3 2026 and $173,607 thousand for the nine months ended September 30, 2026, the filing reported.
  • Cash and cash equivalents: $379,704 thousand as of September 30, 2026, up from $334,517 thousand at December 31, 2025.
  • Total assets: $540,715 thousand as of September 30, 2026, compared to $424,433 thousand at December 31, 2025.
  • Shares outstanding: 85,106,685 Class A Ordinary Shares as of September 30, 2026, up from 71,373,579 at December 31, 2025.
  • Basic and diluted net loss per share: $(0.93) for Q3 2026 and $(2.74) for the nine months ended September 30, 2026, attributable to controlling interest shareholders.

MoonLake Immunotherapeutics Third-Quarter 2026 Financial Results

According to the filing, MoonLake Immunotherapeutics (NASDAQ:MLTX), a Cayman Islands company headquartered in Zug, Switzerland, reported total operating expenses of $79,852 thousand for the three months ended September 30, 2026, comprised of $68,871 thousand in research and development expenses and $10,981 thousand in general and administrative expenses. For the nine months ended September 30, 2026, total operating expenses were $211,536 thousand, with R&D accounting for $173,607 thousand and general and administrative costs totaling $37,929 thousand.

The company's balance sheet as of September 30, 2026 showed total assets of $540,715 thousand, up from $424,433 thousand at December 31, 2025, the filing disclosed. This increase was driven in part by growth in cash and cash equivalents to $379,704 thousand and short-term marketable debt securities of $118,758 thousand. Total liabilities rose to $159,087 thousand from $119,952 thousand at year-end 2025, with long-term debt reported at $100,010 thousand. Total shareholders' equity stood at $381,628 thousand as of September 30, 2026.

The filing reported that the accumulated deficit increased to $673,968 thousand as of September 30, 2026, from $462,911 thousand at December 31, 2025. Interest expense for the nine months ended September 30, 2026 was $7,556 thousand, while other income, net was $9,378 thousand. Income tax expense for the nine-month period was $1,343 thousand. The weighted-average number of Class A Ordinary Shares, basic and diluted, was 85,380,482 for Q3 2026 and 76,908,149 for the nine months ended September 30, 2026.

What Was Disclosed

MoonLake Immunotherapeutics filed its quarterly 10-Q report covering the period ended September 30, 2026, disclosing a nine-month net loss of $211,057 thousand, expanded operating expenses driven primarily by R&D, a growing cash position, and an increased share count of 85,106,685 Class A Ordinary Shares outstanding.